Oxford BioTherapeutics
Oxford BioTherapeutics is an international biotechnology company focused on developing innovative antibody drug conjugates (ADCs) to treat cancer. Our OGAP® target discovery platform - the largest of its kind worldwide - provides a unique range of validated, novel targets identified for a wide range of cancer types.
Through our collaborations with leaders in the field, such as Seattle Genetics, we have assembled each of the component technologies (Antibody- Cytotoxin/linker) to successfully develop our own pipeline of ADC's for cancer.